LBA41 - A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma
| Autor: | Ledermann, J., Sehouli, J., Zurawski, B., Raspagliesi, F., De Giorgi, U., Banerjee, S., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R.L., Mihutiu, S., Markowska, J., Cebotaru, C., Herraez, A. Casado, Colombo, N., Kovalenko, N., Kutarska, E., Hall, M., Belli, R., Zurlo, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v626-v626 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|